KANKancera ABKAN info
$0.18info0.10%24h
Global rank
Market cap$14.32M
Change 7d-1.62%
YTD Performance-57.69%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Kancera AB (KAN) Stock Overview

    Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.

    KAN Stock Information

    Symbol
    KAN
    Address
    Karolinska Institutet Science ParkSolna, 171 65Sweden
    Founded
    -
    Trading hours
    -
    Website
    https://www.kancera.com
    Country
    πŸ‡ΈπŸ‡ͺ Sweden
    Phone Number
    46 8 50 12 60 80

    Kancera AB (KAN) Price Chart

    -
    Value:-

    Kancera AB Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.17574692442882248
    N/A
    Market Cap
    $14.32M
    N/A
    Shares Outstanding
    81.51M
    N/A
    Employees
    4.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org